1 Prophylactic and reactive vaccination strategies for healthcare

2 workers against MERS-CoV

3 Daniel J Laydon^{1,*}, Simon Cauchemez², Wes R Hinsley¹, Samir Bhatt^{1,3}, Neil M Ferguson^{1,*}

¹ MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London,
 Faculty of Medicine, Norfolk Place, London, W2 1PG, UK

- ² Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université de Paris, CNRS
 7 UMR2000, 75015 Paris, France
- 8 ³ Section of Epidemiology, Department of Public Health, University of Copenhagen
- 9 * <u>d.laydon@imperial.ac.uk; neil.ferguson@imperial.ac.uk</u>
- 10

11 Abstract (limit 150 words)

12 Several vaccines candidates are in development against Middle East respiratory 13 syndrome-related coronavirus (MERS-CoV), which remains a major public health 14 concern. Using individual-level data on the 2013-2014 Kingdom of Saudi Arabia 15 epidemic, we employ counterfactual analysis on inferred transmission trees ("who-16 infected-whom") to assess potential vaccine impact. We investigate the conditions under which prophylactic "proactive" campaigns would outperform "reactive" 17 18 campaigns (i.e. vaccinating either before or in response to the next outbreak), 19 focussing on healthcare workers. Spatial scale is crucial: if vaccinating healthcare 20 workers in response to outbreaks at their hospital only, proactive campaigns perform 21 better, unless efficacy has waned significantly. However, campaigns that react at 22 regional or national level consistently outperform proactive campaigns. Measures 23 targeting the animal reservoir reduce transmission linearly, albeit with wide 24 uncertainty. Substantial reduction of MERS-CoV morbidity and mortality is possible 25 when vaccinating healthcare workers, underlining the need for at-risk countries to Stockpile vaccines when available. 26

27 Introduction

The SARS-CoV-2 pandemic has demonstrated the threat posed by novel coronaviruses, the need for effective vaccines and the challenges in optimal vaccine deployment. First identified in the Kingdom of Saudi Arabia (KSA) in 2012 [1-3], Middle East respiratory syndrome–related coronavirus (MERS-CoV) remains a major public health concern, with 2585 laboratory confirmed cases and 931 deaths having been reported in 27 countries as of 16 March 2021 [4].

34

Human-to-human transmission occurs primarily in nosocomial settings but is otherwise relatively rare [5], and dromedary camels constitute the animal reservoir [6-8]. However, the threat of major outbreaks arising from human-to-human transmission should not be underestimated: a single introduction of the virus to South Korea caused 186 cases and 38 deaths in May-July 2015 [9].

40

41 Like SARS-CoV-2, MERS-CoV infection can be asymptomatic or fatal [10]. MERS-42 CoV has a lower transmissibility but higher lethality than SARS-CoV-2, with the 43 Infection Fatality Ratio (IFR) increasing broadly with age in each [10, 11]. While it is 44 not known whether MERS-CoV can transmit presymptomatically or asymptomatically 45 like SARS-CoV-2 [12], sporadic infections in people with no known animal contact or 46 human exposures suggests that asymptomatic or sub-clinical transmission is possible 47 [13]. Estimates of the MERS-CoV IFR vary widely by country and study: in KSA and 48 the Middle East, estimates range from 22% to 69%, whereas in South Korea mortality 49 estimates ranged between 15% and 48% [1]. The IFR calculated using only laboratory 50 confirmed cases is to date 36%. Similarly, the reproduction number (R) is thought to

have been below 1 in Saudi Arabia and the Middle East but between 2.5 and 8.1 in
South Korea [1].

53

No antivirals or vaccines against MERS-CoV are yet licensed [14], although several vaccine candidates are in development [15-18]. The most advanced candidates are the University of Oxford & Janssen Vaccines ChAdOx1 MERS recombinant viral vector vaccine [14], which phase 1b trials have recently shown to be safe, and to elicit both antibody and T cell immune responses in humans [19], and Inovio Pharmaceuticals' INO-4700 nucleic acid vaccine, which is currently in phase 2 trials [20, 21].

61

62 In this study, we build on previous work [6] that inferred transmission trees ("who 63 infected whom" analysis) to estimate the MERS-CoV reproduction number, serial 64 interval, and the contributions of the animal reservoir and human-to-human 65 transmission to the 2013-2014 epidemic in the KSA. This dataset is a detailed 66 individual-level line list of a well described epidemic, and so allows us to address 67 several questions: what would be the impact of a viable vaccine? Is it possible to substantially reduce morbidity and mortality if vaccinating healthcare workers only? 68 69 What would be the optimal strategy to limit case numbers and deaths, and would this 70 optimal strategy depend upon either vaccine efficacy or its duration of protection? If a 71 vaccine cannot be assumed to maintain its efficacy permanently, would a "reactive" 72 vaccination campaign, whereby vaccinations start in response to an outbreak, reduce 73 case numbers more than a prophylactic "proactive" campaign that may occur years

before the next outbreak? To what extent would control measures targeting the animalreservoir mitigate an epidemic?

76

We further use the inferred transmission trees because they preserve spatial properties of the epidemic by estimating the contributions of nosocomial, within-region, between-region and animal reservoir transmission. Using this approach further limits model assumptions, in that downstream effects of vaccination can simply be recorded.

81

We focus our analysis on healthcare workers since nosocomial transmission of MERS-CoV renders them the most at-risk population, and because they could feasibly be identified and vaccinated, either in preparation of future outbreaks, or at pace in response to an ongoing outbreak.

86

87 Methods

88 Data

We employ a line list [6] that includes the day of symptom onset, hospital, region, sex, 89 90 healthcare worker status and clinical outcome of 681 cases of the 2013-2014 MERS-91 CoV outbreak in the KSA. Cases with symptom onset between 1st January 2013 and 92 31st July 2014 were included in the analysis. These data were previously used [6] to probabilistically infer transmission trees within a Bayesian framework. In this study we 93 94 employ a counterfactual analysis whereby we "prune" the inferred transmission trees 95 to evaluate a given strategy, considering what would have happened if a MERS-CoV 96 vaccine had been available to healthcare workers. We can therefore limit assumptions 97 on the extent to which vaccination would prevent transmission, and instead simply
98 delete cases and their secondary cases (in this instance nodes and branches of the
99 transmission tree) and then record the outcome.

100

101 Transmission tree inference

102 The transmission tree inference we use has been described previously [6], but is 103 included in the supplementary information for completeness. Broadly, inference is in 104 two parts: i) inference of parameters; and ii) data augmentation for the infector of each 105 case. Joint posterior estimates of the parameters and augmented data are generated 106 using Markov chain Monte Carlo (MCMC) sampling. Each posterior sample therefore 107 includes, in addition to parameters associated with the reproduction number and serial 108 interval, a transmission tree. The following section discusses the generation of 109 counterfactual posterior samples for given values of vaccine efficacy and duration, 110 using a variety of vaccination strategies.

111

112 Counterfactual transmission trees with vaccination

113 If case $k \in \mathbb{N}$ has infector $i(k) \in \mathbb{N}$, and symptom onset at time $t_k \in \mathbb{N}$, then let $\psi_k \subset \mathbb{N}$ 114 denote the set of all secondary cases from case k, i.e.

115
$$\psi_k = \{m: i(m) = k\}$$

and so therefore (the infector of the secondary cases from case *k* is case *k*)

117 $i(\psi_k) = k$.

Then let $\psi_k^* \subset \psi_k$ denote the set of secondary cases from case *k*, if case *k* had been vaccinated and protected. We assume that protection from disease also protects against onward transmission entirely, i.e. $\psi_k^* = \phi$, the empty set. Therefore, all downstream cases are deleted.

122

123 We consider two broad categories of vaccine campaign, which we name "proactive" 124 and "reactive". Under a proactive campaign, target vaccinees are vaccinated before 125 an outbreak occurs, and so vaccinees are afforded at least some protection at the start 126 of an outbreak. However, a proactive campaign has the obvious disadvantage that it 127 is impossible to predict when the next outbreak will occur. Further, if the vaccine does 128 not maintain its efficacy permanently, then efficacy may have waned substantially by 129 the time the vaccine is actually needed. Recent experience with SARS-CoV-2 130 vaccines [22-27] suggests that waning of vaccine-induced immunity is highly plausible 131 for a MERS-CoV vaccine.

132

133 Therefore, we also consider reactive vaccination campaigns that do not attempt to 134 inoculate the population before the next outbreak, but rather in response to the current 135 outbreak. While this has the disadvantage that the first cases in any outbreak will be 136 left unprotected, it is possible that cases and deaths arising from slow react times 137 would be outweighed by those arising from the suboptimal protection from a waning 138 vaccine. Alternatively, elimination of downstream cases may mean that stopping as 139 many early cases as possible, even with a vaccine of diminished efficacy, is more 140 important than having the highest efficacy possible for the majority of would-be cases.

141

142 An advantage of a reactive campaign is that the vaccine would provide its maximum 143 protection even if waning is substantial. However, the success of such a campaign is 144 dependent on the speed with which target vaccinees are vaccinated, and the delay 145 between vaccination and protection. We consider three levels of reactive campaign, 146 whereby: i) cases within a given hospital would have been vaccinated in response to 147 the first case in that hospital; ii) cases within a given region would have been 148 vaccinated in response to the first case in that region (regardless the hospital in which the first case occurred); iii) cases within all regions would have been vaccinated in 149 150 response to the first case in the country (regardless of the region in which the first case 151 occurred). We are keen that each strategy we consider could at least in principle be 152 implemented as policy, even if the required react times would prove challenging in 153 practice.

154

Let the initial vaccine efficacy be denoted *VE*. In our main analysis, we assume exponential waning of efficacy, and if *D* is the vaccine's mean efficacy duration, then efficacy after t^* years post vaccination is given by

158
$$VE^{*}(t^{*}) = VE \exp(-t^{*}/D).$$

159 As a sensitivity analysis, we also consider slower waning of immunity using the 160 sigmoidal Hill function, and so in this case

161
$$VE^*(t^*) = VE\left(1 - \frac{(t^*/Y)^a}{1 + (t^*/Y)^a)}\right)$$

where Y is the efficacy half-life and *a* governs the speed of decline. We set a = 4 as a balance between allowing the vaccine to maintain its efficacy for longer than exponential waning, while also having a reasonably gradual decline [Figure 1].

165

We consider mean durations (or half-lives if waning is sigmoidal) of 1, 2, 5, 10, 15, and 20 years, as well as no vaccine waning. We simulate values of 6 months, and 1 to 10 years for the time between vaccination and the next outbreak (which we term the "wait" for brevity).

170



Figure 1: Percentage of initial vaccine efficacy remaining over time A by mean duration,
assuming exponential waning; B by half-life, assuming sigmoidal waning. Mean durations and
half-lives of 1, 2, 5, 10, 15 and 20 years are shown.

175

176 If *S* denotes the set of people to be vaccinated, and P_c is the coverage achieved in a 177 campaign, then under a proactive strategy the probability $P_{v,k}$ that a given case *k* will 178 be vaccinated is given by

179
$$P_{v,k} = \delta_S(k) P_c$$

180 where $\delta_{s}(k)$ is defined as

181
$$\delta_{S}(k) = \begin{cases} 1 & k \in S \\ 0 & k \notin S \end{cases}$$

and the probability that case *k* will be protected, and deleted from the transmissiontree, is

$$184 \qquad P_{\nu,k}VE^*(t_k^*)$$

where t_k^* is the time post vaccination for case *k*. In this work, *S* is the set of healthcare workers, and we assume full coverage (i.e. $P_c = 1$) of this group, although the effects of reduced coverage can simply be obtained through scaling. For example, 45% efficacy with 100% coverage is equivalent to 90% efficacy with 50% coverage.

189

190 Under a reactive campaign, a delay must be incorporated to account for first the react 191 time τ_l between the first case in a hospital (or region or country), and second the lag 192 τ_P between vaccination and protection. Hence the probability that case *k* will be 193 vaccinated is given by the following product

194
$$P_{v,k} = \delta_I(k)\delta_S(k)P_d$$

195 where $\delta_{I}(k)$ is defined as

196 $\delta_{I}(k) = \begin{cases} 1 & t_{k} \ge T_{0,h} + \tau_{I} \\ 0 & \text{Otherwise} \end{cases}$

197 If a reactive campaign takes place at the level of a hospital, we define $T_{0,h}$ as the time 198 of symptom onset of the first case in hospital *h*. However, if reacting at regional or 199 national level, $T_{0,h}$ is defined as the time of symptom onset of the first case in region *h* 200 or the entire country.

201

For reactive campaigns, only the vaccine's initial efficacy is relevant (and not its duration of protection) as vaccine waning will be negligible in the time frames we consider between an outbreak and implementation. Here then the probability that case k will be protected and deleted from the transmission tree, is

206
$$\delta_P(k)P_{v_k}VE$$

207 where $\delta_{P}(k)$ is given by

208
$$\delta_P(k) = \begin{cases} 1 & t_k \ge T_{0,h} + \tau_I + \tau_P \\ 0 & \text{Otherwise} \end{cases}$$

and where we vary τ_l between 0 and 28 days in 2-day intervals. T cell responses to ChAdOx1 MERS peaked at 14 days, and while for antibodies the peak was observed at 28 days, antibody titres were still high at 14 days [19], and therefore we set $\tau_P = 14$ days. It is important to note that if the vaccine takes longer than 14 days-post-dose to confer protection, this is effectively already included in our analysis, as it is really the react time plus the time to protection that is important and so a longer time to protection is essentially a relabelling.

216

217 We investigate the effect of control measures aimed at limiting animal reservoir 218 transmission, which we model as a simple proportion γ of reservoir infections that are stopped. That is, if in a particular posterior sample of a given model run, case *k* has i(k) = 0, then case *k* and all their downstream cases are deleted with probability ς . We consider camel control measure efficacies (values of γ) of 10%, 20%, 30%, 40% and 50%. Camel control measures are considered both in isolation and in combination with vaccination campaigns.

224

For a given strategy, we calculate the proportion of cases and deaths averted, and the change in transmission proportions (from e.g. the animal reservoir or within hospitals). The strategies we model are summarised in Table 1. In both proactive and reactive campaigns, we consider values of initial efficacy in 5% intervals between 5% and 100%.

230

231 Model fitting

In the inference of transmission trees and parameter posteriors, all priors are uniform 232 233 and fitted on a log scale. We performed 55,000 iterations with a burn-in period of 5,000, 234 thinning every 5 iterations, resulting in 10,000 posterior samples per model run. 235 Convergence is assessed visually. The model is coded in C++ and R version 4.0.5 236 [28], using packages "ggplot2" [29] and "igraph" [30] for plotting. All model code, 237 (anonymised) precompiled binaries available data, and at are 238 https://github.com/dlaydon/MERS_VacTrees.

239

240 Results

- 241 Data
- 242 In the 18 months from the start of 2013, there were 681 MERS cases, where date of
- 243 symptom onset and patient's hospital was reported, of which 534 (78%) were
- symptomatic at presentation and 276 (41%) were fatal. 187 (28%) of cases were in
- healthcare workers (HCWs), among whom there were 15 deaths, giving an 8% case-
- fatality ratio among healthcare workers, and comprising only 5% of all 276 deaths. The
- 247 case-fatality ratio among non-HCWs was 53% [Figure 2].





251 Figure 2: Weekly incidence of MERS-CoV cases (A, C) and deaths (B, D) for 2013-2014 252 outbreaks, among healthcare workers (HCW) (A, B) and non-healthcare workers (non-HCW) 253 (**C**, **D**).

254

255 Example model output

256 Figure 3 shows a series of transmission trees ("who-infected-whom" plots) from 257 example model runs with and without vaccination. The trees show the contribution to 258 transmission from the animal reservoir, as well as transmission within hospitals, 259 between hospitals but within regions, and between regions.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.06.22273497; this version posted April 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (C) Proactive, 60% efficacy, (A) No vaccine, (B) No vaccine, (D) Camel control measures tree A: 681 cases tree B: 681 cases 10-year mean duration, only, 50% effective, 6-month wait, tree A: 304 cases tree A: 105 cases Transmission type Within hospital Within region Between regions Animal reservoir

Figure 3: Example transmission trees. **(A)** No vaccine, inferred tree A. **(B)** No vaccine, inferred tree B. **(C)** 60% efficacious vaccine with 10-year mean duration, given in proactive campaign that occurs 6 months before the next outbreak. **(D)** Only control measures targeting transmission from the animal reservoir are considered, 50% efficacy assumed.

261

262 Interventions targeting camels only

263 If humans are unvaccinated and interventions solely target the animal reservoir [Figure

S1], then the mean proportions of cases and deaths averted is largely identical to the

265 effectiveness of control measures. However, credible intervals are very wide, reflecting

the unequal contribution of early cases in each local outbreak to the overall epidemic.

267

268 Proactive campaigns

Under a proactive strategy, healthcare workers are vaccinated in anticipation of the next outbreak, and therefore all vaccinees have at least some protection from its outset. However, a proactive strategy depends on the extent of vaccine waning. Therefore success is a function of initial efficacy, duration and the wait time until the next outbreak, where the latter cannot be known in advance.

274

275 In the absence of camel control measures, under an optimistic scenario of 90% 276 efficacy with a 20-year mean duration and only 6 months until the next outbreak, 64% 277 (95% Crl: 54% - 74%) of cases and 51% (95% Crl: 39% - 64%) of deaths would be 278 averted. However, if the next outbreak occurred 8 years after vaccination, then only 279 54% (95% Crl: 41% - 67%) of cases and 41% (95% Crl: 28% - 58%) of deaths would 280 be averted. The 2013-2014 KSA MERS-CoV outbreak has been the only one of its 281 scale [31], which suggests that the wait until next large outbreak (i.e. an outbreak that 282 will most require vaccination) will be long.

283

284 Figure 4 shows the proportion of cases averted as a function of efficacy, duration, wait 285 between vaccination and the next outbreak, and the effectiveness of camel control 286 measures. Figure S2 shows the equivalent plots for the proportion of deaths averted. 287 The success of a proactive campaign increases with the vaccine's efficacy and 288 duration of protection, and decreases with the wait until next outbreak. The wait 289 between vaccination and outbreak is largely irrelevant if duration is long (e.g. 20 290 years), whereas the duration matters far less for short waits, and so here success is a 291 function primarily of efficacy. In any case, low efficacies (e.g. ≤25%) struggle to make 292 any impact, achieving at most a 31% (95% Crl: 18% - 51%) reduction in cases and 293 23% (95% CrI: 10% - 42%) reduction in deaths. Short durations (≤ 2 years) similarly 294 struggle unless waits are short (<1 year) and efficacy is at least moderate (e.g. \geq 50%).

295



296

Figure 4. Each plot shows the mean posterior estimate of the proportion of cases averted by efficacy (x-axis) and mean duration (y-axis). Deeper blue colours indicate more averted cases. Each column of plots shows a given wait until the next outbreak after vaccination. Waits of 6 months, 1, 2, 4, and 8 years are shown. Each row of plots shows a given efficacy of camel control measures: values of 0% (i.e. no camel control measures), 10%, 30% and 50% are shown.

303

Adding measures targeting the animal reservoir can make large differences to proactive campaigns [Figure 4]. For example, 30% effective camel controls would improve the above optimistic scenario (90% efficacy, 20-year mean duration and 6 months wait) to 75% (95% Crl: 63% - 87%) of cases and 66% (95% Crl: 49% - 83%)

308 of deaths. 50% effective camel control measures would improve this further to 82% 309 (95% Crl: 69% - 92%) of cases and 75% (95% Crl: 57% - 90%) of deaths. Trends with 310 efficacy, duration and wait time hold with the addition of camels, and the uncertainty 311 in modelling camels in isolation is also present in combination with proactive 312 campaigns. Lower credible intervals [Figure S3] show substantially less effective 313 campaigns, whereas upper credible intervals [Figure S4] practically eliminate the 314 epidemic for most values of efficacy, duration, wait time and camel control 315 effectiveness that we considered.

316

317 Reactive campaigns

In the likely event that vaccine efficacy wanes over time, even for a high efficacy and duration, a proactive campaign is still dependent on there being a sufficiently short wait until the next outbreak, at least in the absence of widespread and effective camel control measures.

322

Under a reactive campaign, an outbreak is already underway and so neither the wait until the next outbreak, nor the vaccine's duration of protection are relevant. However, the react time between the first case of an outbreak and the implementation of a vaccination campaign will determine how a vaccine will fare. We model react times in 2-day intervals between 0 and 28 days and assume it takes 14 days for the vaccine to elicit an immune response.

329

In the ideal reactive scenario, with a 100% efficacious vaccine with instant implementation, vaccinating all healthcare workers in response to the first case at hospital level would avert 59% (95% Crl: 51% - 68%) of cases and 48% (95% Crl: 38% - 58%) of deaths. Since healthcare workers constituted only 28% of cases, this discrepancy illustrates the disproportionate effect of removing downstream cases [Figure 5].



Figure 5: Mean posterior estimates for reactive campaigns of the proportion of cases averted, as a function of vaccine efficacy and react time. Left, centre and right columns show campaigns reactive at hospital, regional and national level. Top, middle and bottom rows show reactive campaigns in tandem with camel control measures of 0%, 30% and 50% respectively.

343

If a react time of 14 days is assumed, impact falls to 53% (95% Crl: 43% - 62%) of cases and 42% (95% Crl: 32% - 51%) of deaths, and for a 28-day react time falls further to 51% (95% Crl: 41% - 61%) of cases and 41% (95% Crl: 30% - 51%) of deaths. A vaccine efficacy of 50% with react times zero, 14 and 28 days would respectively reduce cases by 41% (95% Crl: 28% - 55%), 36% (95% Crl: 24% - 51%),

and 35% (95% Crl: 22% - 50%) [Figure 5], and deaths by 32% (95% Crl: 18% - 46%),
28% (95% Crl: 16% - 42%), and 27% (95% Crl: 15% - 42%) [Figure S5]. For reactive
campaigns at hospital level, react times beyond approximately 10 days are irrelevant,
and success is a function of efficacy only. Lower and upper credible intervals are
shown in Figures S6-S7, showing wide ranges in impact, as observed for proactive
campaigns.

356 Greater impact can be achieved where a campaign reacts at regional level [Figure 5], 357 where react times matter less than for hospital-level reactions. A perfect vaccine 358 deployed instantaneously to healthcare workers would achieve a 69% (95% Crl: 61% 359 - 77%) reduction in cases and a 55% (95% Crl: 44% - 67%) reduction in deaths. 360 Assuming a 14-day react time, this falls to 66% (95% Crl: 58% - 74%) of cases and 361 51% (95% Crl: 41% - 62%) of deaths, and a 28-day react time reduces 65% (95% Crl: 362 58% - 73%) of cases and 50% (95% Crl: 41% - 62%) of deaths. Therefore, the react 363 time makes less difference than at hospital level. Reacting at national level offers little 364 further improvement [Figure 5], although interestingly the impact is the same 365 regardless of whether the react time takes zero, 14 or 28 days, reducing cases by 69% 366 (95% Crl: 61% - 77%) and deaths by 55% (95% Crl: 45% - 67%) in each instance.

367

The above national-level reductions are the best that can be achieved from reactive campaigns without camel control measures. For 30% effective camel controls, this maximum impact increases to 78% (95% Crl: 68% - 88%) of cases and 68% (95% Crl: 54% - 84%) of deaths averted, whereas with 50% effective camel controls, 84% (95% Crl: 74% - 93%) of cases and 78% (95% Crl: 62% - 91%) of deaths can be averted.

³⁵⁵

Again, these results are insensitive to whether the national-level react time is zerodays, 14 days, or 28 days.

375

376 The gains that can be achieved from reacting at regional or national level versus 377 hospital level vary by efficacy and react time [Figure S8]. On average, across all 378 efficacies and react times considered, regional and national level reactions offer a 31% 379 and 34% improvement over hospital level reactions. The level at which a reactive 380 campaign takes place is more important for longer react times. For example, there are 381 greater differences (and ratios) between regional and hospital level reactions for an 382 implementation that takes 28-day react time than for an instantaneous implementation. 383 Broadly, the ratio of cases averted between reactive campaign levels decreases with 384 efficacy, although this is mostly due to the limited impact of hospital-based reactive 385 campaigns with low efficacy. However, the absolute difference increases with efficacy. 386 At very long react times, national offers a slight improvement over regional and is 387 approximately 5% better for efficacies above e.g. 60% [Figure S8]. Trends are largely 388 the same for the number of deaths averted.

389

390 Proactive vs. reactive campaigns

Figure 6 shows the ratios of cases averted between proactive and reactive campaigns. If vaccine efficacy does not wane, then the wait time until the next outbreak is irrelevant, and so proactive campaigns will always outperform reactive campaigns. Otherwise, a regional level reactive campaign with a 28-day react time is far superior to a proactive campaign, except where both vaccine duration is long (\geq 15 years) and the wait is short (\leq 1 year). National-level reactive campaigns were superior to

397 proactive campaigns in every scenario we considered. Proactive campaigns require 398 less stringent conditions to outperform hospital-level reactive campaigns, although 399 even here reactive campaigns are superior in approximately half our simulations 400 [Figure 6], and more often if the react time is reduced to say 8 days [Figure S9].



Figure 6. Each plot shows the ratio of cases averted between proactive and reactive (regional) campaigns (proactive / reactive), varying with duration of protection and wait until outbreak after vaccination. Proactive campaigns are compared to reactive campaigns at hospital level (top row), regional level (middle row) and national level (bottom row). Left to right columns show vaccine efficacies of 10%, 50% and 90%. A react time of 28 days is assumed in all plots, as well as a 14-day lag between vaccination and immunity. Ratios less than 1 (left of black contour line) indicate that a reactive campaign averts more cases.

409

The above trends hold almost irrespective of vaccine efficacy. Trends are also relatively insensitive to camel control measure effectiveness [Figure S10], although as their effectiveness increases, there is less proportional difference between proactive and reactive campaigns. Trends further hold when considering the ratio of deaths averted [Figure S11], although hospital- and regional-level campaigns outperform proactive slightly less often.

416

417 There is an asymmetry in the relative performance of proactive and reactive 418 campaigns (if the vaccine does not retain its efficacy permanently). Assuming 10% 419 vaccine efficacy, proactive campaigns can at best avert 39% more cases than 420 hospital-level reactive campaigns, or 31% more cases assuming 90% efficacy. 421 However, regional and national reactive campaigns of a 10% efficacious vaccine can 422 respectively avert approximately 97 and 100 times more cases than a proactive 423 campaign, or 421 and 444 times more if vaccine efficacy of 90% is assumed, albeit 424 with the important caveat than the very poor performance of proactive campaigns with 425 short duration and long wait results in very small numbers being compared.

426

427 Change in transmission type

Figures S12 and S13 respectively show the change in relative and absolute transmission contribution with vaccine efficacy for a number of example scenarios. Without human vaccination, interventions targeting only the animal reservoir simply reduce overall case numbers, and do not change the proportional contributions of each transmission type (nosocomial, regional, national and reservoir). Otherwise, the

433 change in transmission proportions with efficacy is highly similar between strategies. 434 Nosocomial transmission decreases with vaccine efficacy from approximately 60% to 435 between approximately 45% and 50%, depending on the specific strategy. 436 Transmission within hospital, region and nationally goes down and therefore relative 437 contribution of animal reservoir goes up (approximately 12% of cases without 438 vaccination rising to as much as 30% depending on the strategy) [Figure S12]. Trends 439 in absolute case numbers also do not differ markedly between vaccination strategies 440 [Figure S13], although regional reactive campaigns avert more nosocomial, regional 441 and national transmission than hospital level reactive campaigns.

442

443 Sensitivity analyses

We investigated the sensitivity of our results to the choice of vaccine waning model. Our main analysis considers waning of immunity to be exponential. However it may be that a slower decline with a sigmoidal function, would be more appropriate. We therefore reran our analysis of proactive campaigns using a Hill function [Figure 1], considering the vaccine's half-life as opposed to its mean duration.

449

The relationships between the proportion of cases averted and efficacy, duration (in this instance half-life), and the wait until the next outbreak are largely the same as for our default exponential waning model [Figure S14], although longer half-lives (>5 years) perform slightly better and shorter half-lives (<5 years) perform slightly worse. In general though, the predicted impact of proactive campaigns is marginally greater when considering sigmoidal waning.

456

Assuming sigmoidal waning affects the relative performance of reactive and proactive campaigns [Figure S15]. Hospital- and regional-level reactive campaigns are more often eclipsed by proactive campaigns. However, nationally reactive campaigns are still superior to proactive campaigns in almost all simulations. Trends are again consistent across different values of vaccine efficacy, and with camel control effectiveness (not shown). Our results are reasonably robust to the choice of waning model.

464

465 We were further concerned that the timeframe under consideration could bias our 466 comparison of reactive and proactive campaigns. If a campaign reacts to cases 467 (whether at hospital, regional or national level) in 2013, then there is ample time to 468 react before the majority of cases occur during 2014 [Figure 2]. Figures S16-S18 show 469 the comparison between reactive and proactive campaigns after dividing the entire 470 Jan 2013 – Jul 2014 dataset into three subsets (i) Jan-Jun 2013; ii) Jul-Dec 2013, and 471 iii) Jan-Jul 2014). For all three subsets, any advantages previously enjoyed by 472 hospital-level reactive campaigns against proactive suffer substantially, regardless of 473 efficacy: proactive campaigns are usually better, except for short durations and long 474 waits between vaccination and the next outbreak. Regional-level reactive campaigns 475 are affected less consistently: they fare worse for each 2013 data subset, but are 476 almost identical for the 2014 subset. However, campaigns that react at national level 477 consistently outperform proactive campaigns, almost regardless of the timeframe 478 considered, although there is little difference between proactive and reactive 479 campaigns here.

480

It is important to note that where ratios are high, and therefore where proactive campaigns ostensibly avert many times the cases than reactive campaigns, there are very few cases to avert in the first place, particularly among healthcare workers [Figure 2]. Therefore, in situations where there are most cases where a vaccine is most needed, reactive policies at national level are best.

486

487 Discussion

488 No vaccine against MERS-CoV has yet been licensed in humans. If and when such a 489 vaccine becomes available, determining its optimal deployment is nontrivial. In this 490 study, we analysed multiple vaccine campaign strategies as a function of efficacy and 491 duration. Each strategy was evaluated by estimating multiple transmission trees (who-492 infected-whom), and then "pruning" them to generate counterfactual epidemics to 493 determine the number of cases and deaths that a vaccine would prevent. Our intention 494 is that all strategies considered could at least in principle be implemented, and 495 therefore that our analysis will be relevant for policymakers. We considered 496 vaccination of healthcare workers only, as they will be most easily vaccinated and 497 most exposed, and therefore more cost-effective.

498

We considered the relative merits of proactive and reactive campaigns, where the fundamental difference between the two approaches is whether to vaccinate in anticipation of the next outbreak, or in response to the current outbreak. The success of a proactive campaign is a function of vaccine efficacy, duration and the wait time

503 between vaccination and the next outbreak. Whereas for reactive campaigns, success 504 is dependent on efficacy, react time and the spatial level at which a vaccination 505 campaign reacts: in response to a hospital, regional or national outbreak. In all 506 scenarios examined, vaccination has a greater effect on cases than deaths, likely 507 because healthcare workers firstly constitute only 27% of cases, and secondly 508 because they are younger than non-healthcare workers (mean age 39 vs. 51 years) 509 and so are probably healthier.

510

511 Short durations or long waits (or both) greatly diminish the impact of a proactive campaign. While the wait time until the next major outbreak cannot be known in 512 513 advance, still less its magnitude, given that the 2013-2014 KSA MERS-CoV outbreak 514 was the only one of its scale [31], it is reasonable to think that the wait until the next 515 large outbreak will be long. In contrast, we have not modelled reactive campaigns to 516 depend on the vaccine's duration, and so vaccinees are conferred maximum possible 517 benefit, provided that vaccines can be administered and elicit an immune response 518 before people would otherwise be infected.

519

Therefore, the spatial scale at which a campaign reacts is crucial. If each hospital reacts individually to its own outbreak, many cases (and their secondary cases) occur before vaccination or immunity. However, campaigns that react at regional or national level suffer far less from these delays and therefore can avert many more cases than their proactive equivalents, even where the time until the next outbreak is short and durations are long (although proactive campaigns are always better than reactive if vaccine efficacy does not wane). Interestingly, the relative performance of reactive and

527 proactive campaigns does not depend on efficacy, and the introduction of measures 528 to limit transmission from the animal reservoir does not affect the rank order of 529 campaigns. Essentially, regionally and nationally reactive campaigns offer an 530 opportunity to get ahead of the epidemic, and can be viewed as a proactive campaign 531 but with a more certain and shorter wait time.

532

533 Our analysis is reasonably robust to whether vaccine waning is exponential or 534 sigmoidal, but more sensitive to the choice of timeframe, in that hospital-level reactive 535 campaigns are rarely superior to proactive. However, our main conclusions firstly that 536 the spatial scale at which a vaccination campaign reacts is crucial, and secondly that 537 nationally reactive campaigns are campaigns are the most effective way to reduce 538 MERS-CoV case numbers and deaths, are strengthened. Further, focussing on the 539 impact on a single smaller outbreak slightly misses the point: we are ultimately most 540 interested in the maximum possible morbidity and mortality reductions over the widest 541 possible timeframe. In effect this blurs the distinction between reactive and proactive 542 campaigns: a reactive campaign against one outbreak can also be considered as a 543 proactive campaign against a subsequent outbreak.

544

545 We are aware of some limitations in our analysis. We assume that all downstream 546 cases of a successfully inoculated person are deleted, and this is unlikely to be 547 completely true for two reasons. First, if downstream cases had not been infected by 548 their index case, they may still have been infected through another route. Second, the 549 vaccine may have differing efficacies against disease and transmission. A vaccine that 550 inoculates against disease may not stop transmission or vice-versa. Additionally, we

assume there is no age-dependency in vaccine efficacy, and recent experience with SARS-CoV-2 vaccines suggests that that some age-dependency is likely [32-34]. While properly accounting for these issues would improve our estimates, we do not have any data to inform such analysis, and so any attempt to do so would be overly speculative.

556

It is also possible that some sub-clinical infections were not detected, and are therefore missing from our line list. If such cases contributed meaningfully to transmission, then our results could be biased upwards, and arguably more so for reactive campaigns, as reactive campaigns might not react to index case in a hospital or region or country. We have also not accounted for any behavioural change or risk compensation in response to an available vaccine.

563

In considering camel control measures, we have assumed only a simple proportional reduction in contribution from animal reservoir, without specifying what this would entail (e.g. vaccination, better hygiene, or reduced physical contact between humans and camels), and clearly additional data to inform more precise analysis would be helpful.

569

570 To reduce the otherwise prohibitively large number of simulations, we have assumed 571 no vaccine waning under reactive campaigns. However, unless duration was very 572 short the effects of waning would be negligible, and in this instance, waning would still 573 affect reactive campaigns less than proactive campaigns. On the other hand, we 574 assume zero immunity until 14 days post vaccination, whereas in practice there would

575 be at least some protection prior to this. Greater delays between vaccination and 576 immunity would affect our results, but not the trends we describe, and would 577 essentially constitute a relabelling (e.g. if the time was 10 or 18 days, the react times 578 we list must be decreased or increased respectively by 4 days).

579

580 Because MERS-CoV outbreaks are relatively infrequent, traditional randomised 581 controlled trials may not be feasible [35], and therefore vaccine efficacy or its wider 582 effectiveness may be difficult to measure empirically, and this is even more so with the 583 vaccine's duration of protection. It is therefore useful to have an indication of the most 584 effective strategies even if values of efficacy and duration are unknown. Unless the 585 vaccine maintains its efficacy for a long time (>20 years) a reactive campaign at 586 regional or national level will usually be superior to a proactive campaign.

587

588 Our analysis demonstrates that substantial reduction of MERS-CoV cases and deaths 589 is possible even when vaccinating healthcare workers only, and underlines the need 590 for countries at risk of MERS-CoV outbreaks to have reasonably large stockpiles of 591 vaccines when they become available.

592

593 Data sharing statement / Code availability

594 All model code, (anonymised) data, and precompiled binaries are available at 595 https://github.com/dlaydon/MERS_VacTrees.

596

597 Acknowledgements

598 DJL, WRH, SB and NMF acknowledge joint Centre funding from the UK Medical 599 Research Council and Department for International Development (grant 600 MR/R015600/1). DJL and NMF acknowledge funding from Vaccine Efficacy 601 Evaluation for Priority Emerging Diseases (VEEPED) grant, (ref. NIHR: PR-OD-1017-602 20002) from the National Institute for Health Research. SB acknowledges The UK 603 Research and Innovation (MR/V038109/1), the Academy of Medical Sciences 604 Springboard Award (SBF004/1080), The BMGF (OPP1197730), Imperial College 605 Healthcare NHS TrustBRC Funding (RDA02), The Novo Nordisk Young Investigator 606 Award (NNF20OC0059309) and The NIHR Health Protection Research Unit in 607 Modelling Methodology. SC acknowledges financial support from the Investissement 608 d'Avenir program, the Laboratoire d'Excellence Integrative Biology of Emerging 609 Infectious Diseases program (grant ANR-10-LABX-62-IBEID) and the INCEPTION 610 project (PIA/ANR-16-CONV-0005). Views expressed do not necessarily represent 611 those of the funders.

613 Tables

614 **Table 1.** Modelled vaccination campaign strategies.

Description (Symbol)	Values simulated / Comments
Initial vaccine efficacy (VE)	Between 5% and 100% in intervals of 5%
Camel control measure effectiveness (ς)	10%, 20%, 30%, 40%, 50% and 0% (i.e. no measures targeting animal reservoir),
Proactive	
Mean duration (<i>D</i>) / Half-life (<i>Y</i>)	1, 2, 5, 10, 15, 20-year duration (or half-life if considering sigmoidal waning) and infinite duration (i.e. no vaccine waning)
Wait between vaccination and next outbreak (<i>t*</i>)	1 year to 10 years, and 6 months.
Reactive	
Spatial reaction level for reactive campaign	i) hospital; ii) regional; iii) national
React time (τ_i)	0 to 28 days in 2-day intervals, between start of (hospital, regional or national) outbreak and vaccination
Time between vaccination and immunity (τ_P)	14 days (zero immunity assumed between 0 and 13 days post vaccination)

616

References

617

- 618 1. Park J-E, Jung S, Kim A, Park J-E. MERS transmission and risk factors: a systematic review.
 619 BMC Public Health. 2018;18(1):574. doi: 10.1186/s12889-018-5484-8.
- 620 2. Ramadan N, Shaib H. Middle East respiratory syndrome coronavirus (MERS-CoV): A review.
 621 Germs. 2019;9(1):35-42. doi: 10.18683/germs.2019.1155. PubMed PMID: 31119115.
- 3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a
 Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. 2012;367(19):1814-20. doi:
 10.1056/NEJMoa1211721. PubMed PMID: 23075143.

625 4. Food and Agriculture Organization of the United Nations: MERS situation update 2022.

626 Available from: <u>https://www.fao.org/ag/againfo/programmes/en/empres/mers/situation_update.html</u>.

- 5. Cauchemez S, Van Kerkhove MD, Riley S, Donnelly CA, Fraser C, Ferguson NM. Transmission
 scenarios for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and how to tell them apart.
 2013;18(24):20503. doi: doi:<u>https://doi.org/10.2807/ese.18.24.20503-en</u>.
- 630 6. Cauchemez S, Nouvellet P, Cori A, Jombart T, Garske T, Clapham H, et al. Unraveling the 631 drivers of MERS-CoV transmission. 2016;113(32):9081-6.
- 632 7. Dighe A, Jombart T, Van Kerkhove MD, Ferguson NJE. A systematic review of MERS-CoV
 633 seroprevalence and RNA prevalence in dromedary camels: Implications for animal vaccination.
 634 2019;29:100350.
- Aguanno R, Elldrissi A, Elkholy AA, Ben Embarek P, Gardner E, Grant R, et al. MERS: Progress
 on the global response, remaining challenges and the way forward. Antiviral Research. 2018;159:3544. doi: <u>https://doi.org/10.1016/j.antiviral.2018.09.002</u>.
- 638 9. Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological
 639 assessment of MERS-CoV outbreak in South Korea, May to June 2015. 2015;20(25):21163. doi:
 640 doi:<u>https://doi.org/10.2807/1560-7917.ES2015.20.25.21163</u>.
- Lessler J, Salje H, Van Kerkhove MD, Ferguson NM, Cauchemez S, Rodriquez-Barraquer I, et
 al. Estimating the Severity and Subclinical Burden of Middle East Respiratory Syndrome Coronavirus
 Infection in the Kingdom of Saudi Arabia. American Journal of Epidemiology. 2016;183(7):657-63. doi:
 10.1093/aje/kwv452.
- 645 11. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of
 646 coronavirus disease 2019: a model-based analysis. 2020;20(6):669-77.
- 647 12. Savvides C, Siegel R. Asymptomatic and presymptomatic transmission of SARS-CoV-2: A
 648 systematic review. medRxiv. 2020:2020.06.11.20129072. doi: 10.1101/2020.06.11.20129072. PubMed
 649 PMID: 32587980.
- Cauchemez S, Fraser C, Van Kerkhove MD, Donnelly CA, Riley S, Rambaut A, et al. Middle
 East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases,
 and transmissibility. Lancet Infect Dis. 2014;14(1):50-6. Epub 2013/11/13. doi: 10.1016/S14733099(13)70304-9. PubMed PMID: 24239323.

4. van Doremalen N, Haddock E, Feldmann F, Meade-White K, Bushmaker T, Fischer RJ, et al.
A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques.
2020;6(24):eaba8399.

Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, et al. A synthetic
consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory
syndrome coronavirus in nonhuman primates. 2015;7(301):301ra132-301ra132.

Lan J, Yao Y, Deng Y, Chen H, Lu G, Wang W, et al. Recombinant receptor binding domain
protein induces partial protective immunity in rhesus macaques against Middle East respiratory
syndrome coronavirus challenge. 2015;2(10):1438-46.

Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, et al. Evaluation of candidate
vaccine approaches for MERS-CoV. 2015;6(1):1-11.

Wang C, Zheng X, Gai W, Zhao Y, Wang H, Wang H, et al. MERS-CoV virus-like particles
produced in insect cells induce specific humoural and cellular imminity in rhesus macaques.
2017;8(8):12686.

Bosaeed M, Balkhy HH, Almaziad S, Aljami HA, Alhatmi H, Alanazi H, et al. Safety and
immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002):
an open-label, non-randomised, dose-escalation, phase 1b trial. 2021.

Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine
candidate for COVID-19. Nature Communications. 2020;11(1):2601. doi: 10.1038/s41467-020-165050.

674 21. CEPI Vaccine Portfolio. Available from: <u>https://cepi.net/research_dev/our-portfolio/</u>.

675 22. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning676 of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. 2021.

Feikin D, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of
effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 Disease: results of a
systematic review and meta-regression. 2021.

Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of Protection
against Mild and Severe Disease by Covid-19 Vaccines. 2022. doi: 10.1056/NEJMoa2115481.

682 25. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning
683 Immunity after the BNT162b2 Vaccine in Israel. 2021;385(24):e85. doi: 10.1056/NEJMoa2114228.

684 26. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness
685 of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA:
686 a retrospective cohort study. 2021;398(10309):1407-16.

687 27. Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RDJNRI. SARS-CoV-2
688 breakthrough infections in vaccinated individuals: measurement, causes and impact. 2021:1-9.

689 28. Team RCJRFfSC. R: A language and environment for statistical computing (Version 4.0.690 5)[Programming language]. 2021.

691 29. Wickham H, Chang W, Wickham MHJCEDVUtGoGV. Package 'ggplot2'. 2016;2(1):1-189.

692 30. Csardi MGJLa. Package 'igraph'. 2013;3(09):2013.

WHO Middle East respiratory syndrome coronavirus (MERS-CoV) 2022. Available from:
 https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab 1.

695 32. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the 696 mRNA-1273 SARS-CoV-2 vaccine. 2021;384(5):403-16.

697 33. Collier DA, Ferreira IA, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune
698 response heterogeneity to SARS-CoV-2 vaccine BNT162b2. 2021;596(7872):417-22.

699 34. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness

700 of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations,

and deaths following a nationwide vaccination campaign in Israel: an observational study using national
 surveillance data. 2021;397(10287):1819-29.

703 35. Nikolay B, Ribeiro dos Santos G, Lipsitch M, Rahman M, Luby SP, Salje H, et al. Assessing

704 the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh. Vaccine.

705 2021;39(39):5600-6. doi: https://doi.org/10.1016/j.vaccine.2021.08.027.

706

708 Supplementary Methods

709

710 Transmission tree inference

711 Parameter inference

The following has been presented previously [6], but is described here for ease of reference. MERS-CoV cases are partitioned into clusters, where we define a cluster as a group of cases from the same hospital, where the time lag between consecutive cases is at most 21 days. Let ω_s denote the proportion of secondary cases with onset *s* days after the onset of their infector (i.e. the serial interval). ω_s is assumed to be Gamma distributed and its mean and standard deviation are inferred from the data.

718

719 The MERS-CoV reproduction number is divided into three mutually exclusive parts: i) 720 within-cluster; ii) between-cluster and within-region; iii) between-region. $R^{c}_{C}(m)$ 721 denotes the within-cluster reproduction number $R^{c}c(0)$ for cluster c after m cases, and 722 its initial value $R^{c}_{c}(0)$ is drawn from a gamma distribution with mean R_{c} and standard 723 deviation σ_c . $R^c_C(m)$ is given by $R^c_C(m) = R^c_C(0)(1+m)^{-\gamma}$, where γ is a fitted parameter 724 that describes the decline in the reproduction number with the number of cumulative 725 cases, either due to infection control measures or to the depletion of susceptible 726 individuals.

727

The mean number of animal reservoir infections α_t on day *t* is given by $\alpha_t = E_0 \exp(\alpha t)$, where E_0 is the initial number of reservoir infections at the beginning of the study period (i.e. January 1, 2013), and α is the (positive or negative) growth rate.

If case $k \in \mathbb{N}$ has infector $i(k) \in \mathbb{N}$, and is a member of cluster and region c_k and q_k respectively, then the individual reproduction numbers at within-cluster, between cluster and between-region level are given by

735
$$R_{C,k} = \sum_{j:c_j=c_k} \delta(i(j) = k)$$
 (within-cluster)

736
$$R_{R,k} = \sum_{j:c_j \neq c_k, q_j = q_k} \delta(i(j) = k)$$
 (between-cluster and within-region)

737
$$R_{O,k} = \sum_{j:q_j \neq q_k} \delta(i(j) = k)$$
 (between-region)

where $\delta(i(j)=k) = 1$ if i(k) = j and 0 otherwise. We set i(k) = 0 if the k^{th} case was infected by the animal reservoir. Therefore the number of introductions I_t on day t is given by $I_t = \sum_{j: t_j = t} \delta(i(j) = 0)$.

741

The likelihood *L* is composed of three terms concerning: i) transmission between cases L_k^{trans} ; ii) animal reservoir introduction L_t^{intro} ; and iii) heterogeneity of transmission intensity between clusters $L^{cluster}$.

745

747

746 L_k^{trans} is given by

$$\begin{split} L_{k}^{\text{trans}} &= P_{\text{Pois}} \left(R_{C,k} \mid R_{C}^{c_{k}}(m_{c_{k}}(t_{k})) \right) \times P_{\text{Pois}} \left(R_{R,k} \mid R_{R} \right) \times P_{\text{Pois}} \left(R_{O,k} \mid R_{O} \right) \\ & \times \left(H_{qk} - 1 \right)^{-R_{R,k}} \left(H - H_{qk} \right)^{-R_{O,k}} \\ & \times \prod_{j:i(j)=k} \omega(t_{j} - t_{k}) \end{split}$$

where *H* denotes the total number of hospitals in the data, and H_q is the number of hospitals in region *q*. The first line of L_k ^{trans} gives the probabilities of observing secondary cases arising from within-cluster, between-cluster and within-region, and between-region transmission. The second line of L_k ^{trans} gives the probabilities that a secondary case outside of case *k*'s hospital will be in another hospital within region and outside region q_k . The third line of L_k ^{trans} gives the density of the serial interval.

The likelihood L_t^{intro} that there were I_t infections from the animal reservoir on day t is

755
$$L_t^{\text{intro}} = P_{\text{Pois}} \left(I_t \,|\, \alpha_t \right) H^{-I_t}$$

and the likelihood *L^{cluster}* of the heterogeneity of transmission intensity is a product over
 clusters

758
$$L^{\text{cluster}} = \prod_{c} P_{\text{Gamma}} \left(R_{C}^{c}(0) \,|\, R_{C}, \sigma_{C} \right)$$

759 The full likelihood *L* is a product of the above terms

760
$$L = L^{\text{cluster}} \prod_{k} L_{k}^{\text{trans}} \prod_{t} L_{t}^{\text{intro}}$$

761

762 Data augmentation

In practice, the infector of each case is unknown, and so we use data augmentation and infer the joint posterior distribution of the parameters and infectors. For each possible source of infection *k* to case *j*, we define the following weights w_k :

766
$$w_{k,j} = \begin{cases} R_C \omega(t_j - t_k) & c_k = c_j \\ R_R \omega(t_j - t_k) & c_k \neq c_j \text{ and } q_k = q_j \\ R_O \omega(t_j - t_k) & q_k \neq q_j \\ \beta & k = 0 \text{ (reservoir)} \end{cases}$$

- 767 where $\beta = 0.05$. The above weights are normalised so that the probability $p_{k,j}$ that case
- 768 *j* had infector *k* is given by

769
$$p_{k,j} = w_{k,j} / \sum_{l} w_{l,j}$$
.

771 Supplementary Figures





Figure S1. Proportions of cases (A) and deaths (B) averted with effectiveness of

- camel control measures. Mean proportion in red and 95% credible intervals shown in
- 776 pink.



Figure S2. As per Figure 4, but each plot shows the mean posterior estimate of the

779 proportion of deaths averted.



- **Figure S3.** As per Figure 4, but showing lower credible intervals of the proportion of
- 783 cases averted.

784



786 Figure S4. As per Figure 4, but showing upper credible intervals of the proportion of

787 cases averted.



789 Figure S5. As per Figure 5, but showing mean posterior estimates of the proportion

790 of deaths averted.



792 Figure S6. As per Figure 5, for lower credible intervals of proportion of cases

793 averted as a function of efficacy, react time and reaction level.



795 Figure S7. As per Figure 5, for upper credible intervals of proportion of cases

796 averted as a function of efficacy, react time and reaction level.



Figure S8. Comparison of reactive campaign levels. Top and bottom rows respectively
show the ratios of and differences between the proportions of cases averted, by react
time and efficacy. Left, middle and right columns show: i) regional vs. hospital; ii)
national vs. hospital; iii) national vs. regional.



Figure S9. As per Figure 6, but assuming an 8-day react time.



Figure S10. As per Figure 6, but assuming 30% effective camel control measures in

806 tandem with both proactive and reactive campaigns.



Figure S11. *As per Figure 6, but showing ratio of deaths averted, as opposed to cases.*





811 **Figure S12.** Change in relative contributions of transmission types with efficacy.

812 Each plot shows the change in the proportion of overall cases numbers due to i)

813 nosocomial; ii) regional; iii) national transmission and iv) the animal reservoir. Seven

814 example vaccination campaign scenarios are shown: (A) reactive at hospital level;

815 (B) reactive at regional level; (C) reactive at national level; (D) reactive at national

816 level with 30% effective controls targeting camels; (E) Camel controls only (note that

817 x-axis here shows effectiveness of camel control measures, not vaccine efficacy as

818 per other plots); (F) proactive campaign without camel control measures and (G)

819 proactive campaign with 30% effective camel control measures. Reactive campaigns

820 assume 28-day react time. Proactive campaigns assume 5-year mean duration and

821 6 months wait until next outbreak.



823 Figure S13. Change in absolute contributions of transmission types with efficacy. As

- 824 per Figure S12 but showing absolute case numbers by transmission type and
- 825 efficacy / effectiveness, not relative contributions.



Figure S14. As per Figure 4, but showing mean posterior estimates of the proportion

- 828 of cases averted in proactive campaigns assuming that vaccine efficacy wanes
- sigmoidally, and not exponentially as in our main analysis. Note that the y-axes
- 830 denote vaccine efficacy half-life, as opposed to mean duration.



832 Figure S15. As per Figure 6, but where vaccine efficacy wanes sigmoidally, and not

833 exponentially as in our main analysis. Note that the y-axes denote vaccine efficacy

834 half-life, as opposed to mean duration.



Figure S16. As per Figure 6, but showing mean posterior estimates of the proportion

of cases averted if considering vaccination only during Jan-Jun 2013.



Figure S17. As per Figure 6, but showing mean posterior estimates of the proportion

840 of cases averted if considering vaccination only during Jul-Dec 2013.



Figure S18. As per Figure 6, but showing mean posterior estimates of the proportion

843 of cases averted if considering vaccination only during Jan-Jul 2014.